UBS Group
GMAB icon

UBS Group’s Genmab GMAB Stock Holding History

UBS Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Buy
961,053
+662,921
+222% +$17.6M ﹤0.01% 2406
2026
Q1 		$8M Buy
298,132
+113,941
+62% +$3.41M ﹤0.01% 3589
2025
Q4 		$5.67M Buy
184,191
+102,021
+124% +$3.18M ﹤0.01% 3898
2025
Q3 		$2.52M Sell
82,170
-402,697
-83% -$9.81M ﹤0.01% 4743
2025
Q2 		$10M Sell
484,867
-56,135
-10% -$1.15M ﹤0.01% 3079
2025
Q1 		$10.6M Sell
541,002
-899,868
-62% -$18.9M ﹤0.01% 2974
2024
Q4 		$30.1M Buy
1,440,870
+1,380,422
+2,284% +$30.3M 0.01% 1915
2024
Q3 		$1.47M Sell
60,448
-1,960
-3% -$52.4K ﹤0.01% 4287
2024
Q2 		$1.57M Buy
62,408
+12,704
+26% +$360K ﹤0.01% 4006
2024
Q1 		$1.49M Buy
49,704
+2,343
+5% +$68.8K ﹤0.01% 4237
2023
Q4 		$1.51M Sell
47,361
-1,303
-3% -$40.9K ﹤0.01% 4109
2023
Q3 		$1.72M Sell
48,664
-23,958
-33% -$913K ﹤0.01% 3592
2023
Q2 		$2.76M Buy
72,622
+7,418
+11% +$296K ﹤0.01% 3215
2023
Q1 		$2.46M Buy
65,204
+8,249
+14% +$317K ﹤0.01% 3211
2022
Q4 		$2.41M Buy
56,955
+19,349
+51% +$797K ﹤0.01% 3212
2022
Q3 		$1.21M Sell
37,606
-5,323
-12% -$187K ﹤0.01% 3592
2022
Q2 		$1.4M Sell
42,929
-25,401
-37% -$823K ﹤0.01% 3430
2022
Q1 		$2.47M Buy
68,330
+3,065
+5% +$105K ﹤0.01% 3236
2021
Q4 		$2.58M Sell
65,265
-3,853
-6% -$161K ﹤0.01% 3510
2021
Q3 		$3.02M Buy
69,118
+20,576
+42% +$924K ﹤0.01% 3198
2021
Q2 		$1.98M Buy
48,542
+1,919
+4% +$74.1K ﹤0.01% 3582
2021
Q1 		$1.53M Buy
46,623
+22,833
+96% +$859K ﹤0.01% 3832
2020
Q4 		$967K Buy
23,790
+3,696
+18% +$138K ﹤0.01% 4055
2020
Q3 		$736K Buy
20,094
+6,632
+49% +$240K ﹤0.01% 3872
2020
Q2 		$456K Buy
13,462
+7,738
+135% +$211K ﹤0.01% 4218
2020
Q1 		$121K Buy
5,724
+534
+10% +$11.9K ﹤0.01% 5115
2019
Q4 		$116K Buy
5,190
+537
+12% +$11.7K ﹤0.01% 5926
2019
Q3 		$94K Buy
+4,653
New +$91.6K ﹤0.01% 5796

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's GMAB Position: Q2 2026 in Review

UBS Group increased its Genmab (GMAB) stake by 222% in Q2 2026, buying an estimated $17.6M and bringing the position to 961,053 shares worth $26.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

UBS Group first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $30.1M in Q4 2024. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • UBS Group held 961,053 shares of Genmab worth $26.4M as of Q2 2026.
  • UBS Group bought 662,921 Genmab shares in Q2 2026, an estimated $17.6M.
  • Genmab made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2406 holding.
  • UBS Group first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • UBS Group's Genmab position peaked at $30.1M in Q4 2024.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.